SABCS 2023 | Novel PI3K inhibitors for breast cancer

Cynthia Ma, MD, PhD, Washington University, St. Louis, MO, comments on the latest advances in PI3K inhibition for breast cancer. Despite the approval of abemaciclib, toxic adverse events such as hypoglycemia and rash remains a concern. Novel inhibitors including inavolisib are being assessed in the Phase III INAVO120 (NCT04191499), where inavolisib is administered with palbociclib and fulvestrant. Additional selective inhibitors under development include RLY-2608. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.